SCHEMBL732746

SCHEMBL732746

CCOCC1(c2cc(C(=O)OC)cc(N3CCCC3)c2)N=NN=N1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.37
RAB9A P51151 3/20 0.37
KDM4E B2RXH2 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 3/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730949 0.75 KDM4E (0.53) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL3510581 0.74 KDM4E (0.55) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL2276958 0.72 NOTUM (0.49) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL730950 0.70 ALDH1A1 (0.53) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL21817920 0.70 KDM4E (0.45) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL730837 0.69 KDM4E (0.50) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL732745 0.69 ALDH1A1 (0.38) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
Hydrochloric Acid SCHEMBL17113220 0.68 LOXL2 (0.49) NPC1RAB9AKDM4ESMN1; SMN2NPSR1
SCHEMBL733115 0.68 CA1 (0.44) KDM4ESMN1; SMN2ALDH1A1KMT2AMAPT
SCHEMBL14150012 0.67 KDM4E (0.48) NPC1RAB9AKDM4ESMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 NPC1 2438/4885RAB9A 2465/4885KDM4E 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.